adenomas was reviewed.Results The established first-line medical therapy for refractory adenomas is temozolomide, which importantly may increase survival, but clinical trial data are still needed to clearly establish its efficacy, identify biomarkers of response, and clarify eligibility and outcome criteria...
MEDICAL THERAPY : Management of the Refractory PatientMEDICAL THERAPY : Management of the Refractory PatientIn the past, therapeutic options in patients with gastroesophageal reflux disease (GERD) were limited, and the aim of medical therapy was only to limit the severity and duration of symptom epis...
medical therapy with 4 to 5 classes of medication;only 7 patients(8.0%) ultimately proved to be refractory to maximal medical therapy.Patients with refractory unstable angina were more likely to have electrocardiographic changes on anterior chest leads and ST-segment depression was present in 6(85.7...
Surgical treatment is preferred to medical management due to high cure rate and ability to avoid potential side effects of medical therapy. Avoid the temptation to treat with multiple rounds of various antibiotics in an attempt to find the “magic bullet.” Evidence points to stomatitis being an ...
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014;16(6):829-840... T Kaley,I Barani,M Chamberlain,.....
There are strict indications for CAR T-cell therapy. Data of clinical trials of CAR T-cell therapy is not enough. Facing a dying patient on whom all traditional therapies have been tried in vain, the medical team has to cope with the grave challenges in developing a targeted therapeutic regi...
Millions of patients with coronary artery disease (CAD) suffer from refractory angina despite receiving optimal medical therapy. Shockwave Reducer is designed to treat the symptoms of refractory angina through a permanent, controlled narrowing of the coronary sinus.* Shockwave Reducer Overview and MOA ...
Director of the Center of Excellence for Multiple Myeloma and Professor of Medicine, Hematology and Medical Oncology, Mount Sinai.‡“The availability of a cellular therapy like cilta-cel that can be used ear...
therapy were enrolled, and ORR of 75% was observed (2 patients with CR and 4 patients with PR). We firmly believe that the development of second-line follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) will be extremely competitive in the market. We will continue to ...
(HealthDay)—A once-weekly regimen of selinexor, bortezomib, and dexamethasone slows the progression of relapsed or refractory multiple myeloma, according to a study published in the Nov. 14 issue of The Lancet. Sebastian Grosicki, M.D., from the Medical University of Silesia in Katowice, ...